Mersana Therapeutics to Host Conference Call Announcing Third Quarter 2020 Financial Results and Business Updates
Mersana Therapeutics (NASDAQ:MRSN) announced a conference call and webcast on November 9, 2020, at 8:00 a.m. ET. The call aims to discuss its third-quarter financial results for the period ending September 30, 2020, and provide business updates. The company is focused on developing antibody-drug conjugates (ADCs) to target cancers with significant unmet needs. Their lead candidate, XMT-1536, is currently in a Phase 1 trial for ovarian cancer and NSCLC adenocarcinoma, while XMT-1592 is in a dose escalation Phase 1 trial targeting NaPi2b-expressing tumors.
- None.
- None.
CAMBRIDGE, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will host a conference call and webcast on Monday, November 9, 2020 at 8:00 a.m. ET to report financial results for the third quarter ended September 30, 2020 and provide business updates.
To access the call, please dial 877-303-9226 (domestic) or 409-981-0870 (international) and provide the Conference ID 7953159. A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com.
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana’s lead product candidate, XMT-1536, is in the expansion portion of a Phase 1 proof-of-concept clinical study in patients with ovarian cancer and NSCLC adenocarcinoma. XMT-1592, Mersana’s second ADC product candidate targeting NaPi2b-expressing tumors, was created using Mersana’s customizable and homogeneous Dolasynthen platform and is in the dose escalation portion of a Phase 1 proof-of-concept clinical study. The Company’s early stage programs include a B7-H4 targeting ADC, as well as a STING-agonist ADC developed using the Company’s Immunosynthen platform. In addition, multiple partners are using Mersana’s Dolaflexin platform to advance their ADC pipelines.
Contact:
Investor & Media Contact
Sarah Carmody, 617-844-8577
scarmody@mersana.com
FAQ
What is the date of Mersana Therapeutics' financial results conference call?
What financial results will Mersana Therapeutics report?
What clinical trials is Mersana Therapeutics currently conducting?
